Acazicolcept

艾卡泽西普

Report date: 2025/02/20 10:08:57

First In Class

Base Information

Drug NameAcazicolcept

Drug Alias NameAcazicolceptumALPN-101

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionInducible T-cell costimulator inhibitorsT-cell-specific surface glycoprotein CD28 inhibitors

TargetsInducible T-cell costimulatorT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsInflammationGraft vs Host DiseaseAutoimmune Diseases +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwanPoland +[8]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAlpine Immune Sciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesAlpine Immune Sciences Inc Abbvie Inc

Inactive CompaniesN/A

Active IndicationsInflammationAutoimmune DiseasesLupus Erythematosus, Systemic +[4]

Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A